Abstract
Detection of cancer by analysis of circulating cell-free DNA (cfDNA) has received enormous attention over the past years (Alix-Panabieres and Pantel, 2016). cfDNA is released into the blood circulation by apoptotic and necrotic cells, and cancer patients have increased concentrations of cfDNA (Schwarzenbach et al., 2011). With the development of novel technologies it is now possible to detect tumor-associated mutations on cfDNA and monitor the evolution of cancer progression in patients (Bettegowda et al., 2014). However, the detection of very low amounts of circulating tumor-derived DNA (ctDNA) in blood samples from early stage cancer patients is still a challenge. ctDNA was revealed in only 48–73% of patients with localized cancers including lung cancer (Bettegowda et al., 2014, Newman et al., 2014).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
